Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · Real-Time Price · USD
316.27
-0.56 (-0.18%)
At close: Nov 12, 2026, 4:00 PM EST
317.00
+0.73 (0.23%)
After-hours: Nov 12, 2026, 7:59 PM EST
Ligand Pharmaceuticals Analyst Ratings
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $358 | Buy | Reiterates | $358 | +13.19% | Nov 12, 2026 |
| Barclays | Barclays | Buy Reiterates $345 → $350 | Buy | Reiterates | $345 → $350 | +10.66% | Nov 11, 2026 |
| Citi | Citi | Buy Maintains $397 → $402 | Buy | Maintains | $397 → $402 | +27.11% | Nov 5, 2026 |
Unknown Analyst Leerink Partners No rating | Leerink Partners | Buy Reiterates $330 → $350 | Buy | Reiterates | $330 → $350 | +10.66% | Nov 2, 2026 |
| RBC Capital | RBC Capital | Buy Reiterates $357 | Buy | Reiterates | $357 | +12.88% | Nov 2, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Maintains $406 | Buy | Maintains | $406 | +28.37% | Oct 30, 2026 |
| Oppenheimer | Oppenheimer | Buy Maintains $334 → $346 | Buy | Maintains | $334 → $346 | +9.40% | Oct 30, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Maintains $332 → $350 | Buy | Maintains | $332 → $350 | +10.66% | Oct 30, 2026 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 3 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.